Liver Cancer — Trials, FDA Actions & Pivotal Research
12 updates aggregated from openFDA and ClinicalTrials.gov, covering trial milestones, FDA actions, and pivotal publications about Liver Cancer.
Synced daily from openFDA and ClinicalTrials.gov. Last sync: .
Drugs with Liver Cancer trials
Recruiting trials by city
Cities where Liver Cancer trials in our archive had recruiting sites. Each link lists every currently recruiting paid clinical trial at that location.
Updates
2026
- Results postedPembrolizumab Adjuvant HCC Trial: Higher AE Rate, No Significant QoL Benefit· Apr 24, 2026· drug: Pembrolizumab
- Results postedLiver Cancer: NOLA Registry Details Microwave Ablation Success Rates· Apr 17, 2026
- Results postedPembrolizumab Combination Trial for Solid Tumors Reports DLTs at High Dose· Mar 27, 2026· drug: Pembrolizumab
- Primary completionNivolumab Hepatocellular Carcinoma Trial Completes Primary Endpoint Study· Feb 27, 2026· drug: Nivolumab
- Results postedHepatocellular Carcinoma Biopsy Imaging Trial Results Posted· Feb 2, 2026
2025
- Results postedNivolumab: Safety Data Posted for Advanced Liver Cancer Trial· Dec 24, 2025· drug: Nivolumab
- Results postedAtezolizumab/Cabozantinib Combo Improves PFS in Advanced HCC Trial· Dec 11, 2025· drug: Atezolizumab
- Results postedPembrolizumab Combination Trial for Advanced Solid Tumors Terminated· Nov 17, 2025· drug: Pembrolizumab
- Primary completionLiver Cancer: Phase 3 TACE+RFA vs. TACE Alone Trial Completes Primary· Oct 31, 2025
- Results postedNivolumab/BMS-986253 Combo Shows Higher ORR in HCC Trial· Oct 16, 2025· drug: Nivolumab
- Results postedPembrolizumab + Radiotherapy Shows 41% ORR in Advanced Liver Cancer· Jul 25, 2025· drug: Pembrolizumab
- Results postedPembrolizumab Combo Shows 20% ORR in ESCC, Varied Responses in GI Cancers· Jul 1, 2025· drug: Pembrolizumab